Latest News

FDA grants orphan drug status to irinotecan ChemoSeed implant for high-grade gliomas, enabling sustained local brain tumor therapy and accelerating pivotal trials.

Early results from TALAPRO-3 suggest that the combination of talazoparib and enzalutamide may redefine the treatment paradigm for HRR gene-mutated mCSPC, demonstrating that targeting DNA damage repair earlier in the disease course substantially delays radiographic progression.

FDA clears teclistamab plus daratumumab for early-relapse multiple myeloma, delivering striking PFS gains and scalable outpatient use.

During a live event, Catherine Coombs, MD and participants debate frontline CLL BTK inhibitors: who benefits from continuous therapy, acalabrutinib vs zanubrutinib nuances, and pirtobrutinib's future role.

FDA clears MyChoice CDx to find HRD-positive advanced ovarian cancer patients for niraparib, using BRCA and genomic instability testing.

The combination of nogapendekin alfa inbakicept-pmln (Anktiva) and Bacillus Calmette-Guérin was added to the NCCN clinical guidelines for bladder cancer, according to the manufacturer.

Aglatimagene besadenovec intratumoral gene therapy plus valacyclovir shows durable survival in ICI-resistant advanced NSCLC, fueling pivotal phase 3 plans.

Three-year follow-up data from the phase 3 RATIONALE-309 trial show that tislelizumab plus chemotherapy provides durable progression-free survival and a clinically meaningful overall survival advantage over placebo in recurrent or metastatic nasopharyngeal carcinoma.

A single-arm study of a BCMA CAR T-cell therapy after induction for newly diagnosed multiple myeloma led to 100% minimal residual disease negativity at 3 months.

COMPASSION-03 follow-up shows cadonilimab delivers durable survival in recurrent/metastatic cervical cancer, including PD‑L1–negative patients.

Phase 1 expansion shows Varseta-M delivers notable response rates and manageable safety in heavily pretreated metastatic colorectal cancer, with FDA registrational planning underway.

During a live event, Shaji Kumar, MD, discussed dose deescalation as a strategy for managing adverse events with talquetamab in multiple myeloma.

Digital twin modeling plus metabolomics predicts which drugs can starve glioblastoma, enabling faster, personalized treatment testing.

A real-world analysis of patients receiving teclistamab prior to 2022 showed comparable outcomes to clinical trials and indicated adoption of proactive adverse event management.

Ozekibart, irinotecan, and temozolomide yielded a high response rate and maintained tolerability in patients with relapsed/refractory Ewing sarcoma.

Data presented at ESMO Targeted Anticancer Therapies Congress 2026 support ongoing phase 3 evaluation.

Phase 3 NSCLC study of eftilagimod alfa with pembrolizumab and chemo stops early after futility review, raising questions about LAG-3 strategy.

In an interview, Paul G. Richardson, MD, gave an overview of the ways that CELMoDs are poised to impact the landscape of multiple myeloma treatment at various stages of disease treatment.

During a live event, Marc J. Braunstein, MD, PhD, and participants discussed maintenance lenalidomide and daratumumab as well as the clinical potential of MRD in multiple myeloma.

FDA signals accelerated path for givastomig in CLDN18.2+ gastric/GEJ cancer, as phase 1b data show strong responses and tolerability.

A 31-gene expression profile–based sentinel lymph node biopsy risk model, i31-SLNB, demonstrated a role in predicting lymph node positivity in T1b to T2a melanoma.

Oncology shifts fast: tazemetostat pulled, giredestrant PFS miss, and new ADC and NSCLC guideline strategies refine metastatic care.

Imaging suggests HCC, yet cirrhosis is uncertain—see why biopsy matters and how AFP, spread, and liver function shape treatment.

Report finds hospitals price the same cancer drugs up to 2000x apart, worsening financial toxicity and intensifying demands for real transparency.

Denileukin diftitox brings a new systemic option for relapsed CTCL, killing tumor cells and Tregs to boost immunity and expand EU access.

Interim phase 1b results show off-the-shelf CD19 CAR T azer-cel drives high response rates in hard-to-treat CLL/SLL and MZL.

Fifty patients are enrolled to receive EBX-102-02 or placebo to address gut microbiome disruption associated with allogeneic hematopoietic cell transplant.

Breast cancer care shifts fast: ADCs reach HER2-low, neoadjuvant regimens evolve, and ctDNA MRD testing sparks 2026’s debate.

In this interview, Sagar Lonial, MD, discusses the EXCALIBER-RRMM trial design and the potential role of iberdomide in the evolving therapeutic landscape of multiple myeloma.